Sistema de Salut de Catalunya
Institut Català de la Salut
[Tabernero J] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Institute of Oncology (VHIO), Barcelona, Spain. [Taieb J] Service d'hépatogastroentérologie et d'oncologie digestive, Université de Paris, Paris Descartes University, Georges Pompidou European Hospital, 20 rue Leblanc, Paris, France. [Prager GW] Department of Medicine I, Comprehensive Cancer Centre Vienna, Medical University Vienna, Josefstaedter Str. 23/15, Vienna, Austria. [Ciardiello F] Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Via S. Pansini, Naples, Italy. [Fakih M] Briskin Center for Clinical Research, Section Head and GI Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 E Duarte St, Duarte, CA, USA. [Leger C] Institut de Recherches Internationales Servier, 50 rue Carnot, Suresnes Cedex, France
Vall d'Hebron Barcelona Hospital Campus
2021-07-09T12:37:00Z
2021-07-09T12:37:00Z
2021-06
Bevacizumab; Càncer colorectal metastàtic; Trifluridine/tipiracil
Bevacizumab; Cáncer colorrectal metastásico; Trifluridine/tipiracil
Bevacizumab; Metastatic colorectal cancer; Trifluridine/tipiracil
Trifluridine/tipiracil (FTD/TPI) is an orally active formulation of trifluridine, a thymidine-based nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine. Preliminary studies of FTD/TPI plus bevacizumab have produced encouraging results in the treatment of refractory metastatic colorectal cancer. Here, we describe the design of the multinational Phase III SUNLIGHT, an open-label study of FTD/TPI plus bevacizumab as third-line treatment for patients with unresectable metastatic colorectal cancer. A total of 490 patients will be randomized 1:1 to receive either FTD/TPI plus bevacizumab, or FTD/TPI monotherapy. The primary objective is to significantly improve overall survival with FTD/TPI plus bevacizumab compared with FTD/TPI monotherapy. The first patient was enrolled in November 2020.
Article
Published version
English
Medicaments antineoplàstics - Ús terapèutic; Recte - Càncer; Còlon - Càncer; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols; Other subheadings::Other subheadings::/therapeutic use; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada; Otros calificadores::Otros calificadores::/uso terapéutico
Future Medicine
Future Oncology;17(16)
https://www.futuremedicine.com/doi/10.2217/fon-2020-1238
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]
